Day One Biopharmaceuticals Acquires Mersana Therapeutics

Servier Acquires Day One Biopharmaceuticals for About $2.5 Billion

March 6, 2026

Pharmaceuticals

Servier entered into a definitive agreement to acquire Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company, in a cash deal valued at about $2.5 billion. Servier will pay $21.50 per share and expects the transaction to close in the second quarter of 2026, subject to customary regulatory approvals and tender conditions.

Merck & Co. Acquires Cidara Therapeutics

January 8, 2026

Biotechnology

Merck & Co., through subsidiary Merck Sharp & Dohme LLC, completed a cash tender offer to acquire Cidara Therapeutics, Inc. for $221.50 per share, making Cidara a wholly owned subsidiary. The acquisition adds Cidara's long-acting antiviral candidate CD388 to Merck's respiratory portfolio and is being accounted for as an asset acquisition.

Novo Nordisk Acquires Dicerna Pharmaceuticals

November 18, 2021

Biotechnology

Novo Nordisk entered into a definitive agreement to acquire Dicerna Pharmaceuticals for $38.25 per share in cash, valuing the deal at about $3.3 billion, to accelerate and expand Novo Nordisk’s RNAi therapeutics research. The acquisition was completed in December 2021, with Dicerna becoming a wholly owned subsidiary of Novo Nordisk.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

Genmab A/S Acquires Merus N.V. via Tender Offer

December 12, 2025

Biotechnology

Genmab A/S, through its wholly owned purchaser Genmab Holding II B.V., completed a tender offer to acquire outstanding common shares of Merus N.V. for $97.00 per share and commenced a subsequent offering period. The acquisition adds Merus' lead late‑stage oncology asset petosemtamab to Genmab's portfolio, expanding its antibody therapeutics pipeline and expected to be accretive to EBITDA by 2029.

Bristol Myers Squibb to Acquire Mirati Therapeutics in $4.8B Cash-and-CVR Deal

October 13, 2023

Pharmaceuticals

Bristol Myers Squibb has entered into a definitive merger agreement to acquire Mirati Therapeutics for $58 per share in cash, valuing the transaction at $4.8 billion in equity value. The deal also includes a non-tradeable contingent value right (CVR) that could provide up to an additional $1 billion of value tied to regulatory acceptance of an NDA for Mirati’s MRTX1719.